Marin C, Parashos S A, Kapitzoglou-Logothetis V, Peppe A, Chase T N
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892.
Pharmacol Biochem Behav. 1993 May;45(1):195-200. doi: 10.1016/0091-3057(93)90104-2.
The contribution of D1 and D2 dopamine (DA) receptor mechanisms to the behavioral supersensitivity and receptor upregulation induced by chronic DA antagonist administration were compared. Rats received either the selective D1 DA receptor antagonist SCH23390, the selective D2 DA receptor antagonist raclopride, their combination, or haloperidol, a predominantly D2 antagonist, for 21 days. Equivalent cataleptogenic doses of all drugs and drug combinations were employed. Tolerance to the cataleptic response was observed only in the haloperidol-treated group. Apomorphine-induced stereotypies were significantly enhanced in SCH23390-, raclopride-, and haloperidol-treated rats. In contrast, coadministration of both SCH23390 and raclopride had no effect on apomorphine-induced stereotypy. These findings suggest that neuroleptics blocking in equal proportion D1 and D2 receptor sites might be less likely to induce tardive dyskinesia and drug tolerance than those acting selectively on one or the other of these receptor subtypes.
比较了D1和D2多巴胺(DA)受体机制对慢性给予DA拮抗剂所诱导的行为超敏反应和受体上调的作用。大鼠连续21天接受选择性D1 DA受体拮抗剂SCH23390、选择性D2 DA受体拮抗剂雷氯必利、二者的组合或氟哌啶醇(一种主要作用于D2的拮抗剂)。所有药物及药物组合均采用等效的致僵剂量。仅在氟哌啶醇治疗组中观察到对僵住反应的耐受性。阿扑吗啡诱导的刻板行为在接受SCH23390、雷氯必利和氟哌啶醇治疗的大鼠中显著增强。相比之下,同时给予SCH23390和雷氯必利对阿扑吗啡诱导的刻板行为没有影响。这些发现表明,与选择性作用于这些受体亚型之一的药物相比,同等比例阻断D1和D2受体位点的抗精神病药物可能不太容易诱发迟发性运动障碍和药物耐受性。